Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)

By sjmartinez • August 16, 2023

Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Bengtsson T, Rickard K, Sciurba F. Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials). Am J Respir Crit Care Med. 2023 Aug 15;208(4):406-416. doi: 10.1164/rccm.202306-0944OC. PMID: 37364283.

Tags: COPD, dual PDE3 and PDE4 inhibitor, ensifentrine, nebulized therapy, Publications, Pulmonary, Critical Care & Sleep Medicine

American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults

O'Dwyer K, Winestone LE, Cheung MC, Benitez L, Buldini B, Cole PD, Damlaj M, Dholaria B, Dias AL, Dils A, Fritsch M, Greer J, Hayes-Lattin[...]

Quality measures in the design, conduct, and reporting of endoscopic research

Elmunzer BJ, Madhoun M, Cote GA, Cummings LC, Shahidi N, Srivastava N, Essex EA, Scheiman JM, May FP, Yen T, Barkun A, Durkalski-Mauldin V, Dominitz[...]

Premature Ventricular Contractions Ablated via the Left Ventricular Annular Vein: Demonstration of 3 Possible Approaches

Kanzaki Y, Morishima I, Mori S, Shimojo K, Tanaka Y, Yamada T. Premature Ventricular Contractions Ablated via the Left Ventricular Annular Vein: Demonstration of 3[...]